Patient and family attitudes toward schizophrenia treatment

Current Psychiatry Reports

Volumn 6, Issue 4, 2004, Pages 283-288

  Irani, Farzin ^b   Dankert, Mary ^b   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUOXETINE; NEUROLEPTIC AGENT;

AKATHISIA; BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG EFFICACY; DYSPHORIA; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FAMILY LIFE; HEALTH SURVEY; HUMAN; HYPERKINESIA; HYPOKINESIA; PATIENT ATTITUDE; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL ADAPTATION; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 4444235587     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0078-9     Document Type: Review

References (39)

1. Navon L, Ozer N: Ordinary logic in unordinary lay theories: a key to understanding proneness to medication nonadherence in schizophrenia. Arch Psychiatr Nurs 2003, 17:108-116.
2. Stark FM, Stolle R: [Schizophrenia: subjective illness theories-an explorative study. 1: patients]. Psychiatr Prax 1994, 21:74-78.
3. Ullrich J, Ulmar G, Starzinski T: [Disease models and change in attitude of involuntarily admitted schizophrenic patients]. Fortschr Neurol Psychiatr 1995, 63:480-486.
4. Larsen EB, Gerlach J: Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996, 93:381-388.
5. Poulsen HD, Engberg M: Validation of psychiatric patients' statements on coercive measures. Acta Psychiatr Scand 2001, 103:60-65.
6. Irani F, Dankert M, Brensinger C, et al.: Patient attitude towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology 2004, 29:960-968.
7. Jungbauer J, Wittmund B, Dietrich S, Angermeyer MC: Subjective burden over 12 months in parents of patients with schizophrenia. Arch Psychiatr Nurs 2003, 17:126-134.
8. North CS, Pollio DE, Sachar B, et al.: The family as caregiver: a group psychoeducation model for schizophrenia. Am J Orthopsychiatry 1998, 68:39-46.
9. Dyck DG, Short R, Vitaliano PP: Predictors of burden and infectious illness in schizophrenia caregivers. Psychosom Med 1999, 61:411-419.
10. McDonell MG, Short RA, Berry CM, Dyck DG: Burden in schizophrenia caregivers: impact of family psychoeducation and awareness of patient suicidality. Fam Process 2003, 42:91-103.
11. Schulz PM, Schulz SC, Dibble E, et al.: Patient and family attitudes about schizophrenia: implications for genetic counseling. Schizophr Bull 1982, 8:504-513.
12. Angermeyer MC, Matschinger H: The effect of personal experience with mental illness on the attitude towards individuals suffering from mental disorders. Soc Psychiatry Psychiatr Epidemiol 1996, 31:321-326.
13. Kampman O, Lehtinen K, Lassila V, et al.: Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res 2000, 45:223-234.
14. Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
15. Naber D, Moritz S, Lambert M, et al.: Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001, 50:79-88.
16. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
17. Hellewell JS: Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002, 16:457-471.
18. Castle D, Morgan V, Jablensky A: Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 2002, 36:633-641.
19. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361:1581-1589.
20. Gerlach J, Larsen EB: Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 1999, 395:113-117.
21. Sajatovic M, Rosch DS, Sivec HJ et al.: Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002, 53:1319-1321.
22. Garavan J, Browne S, Gervin M, et al.: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics: attitudes to medication and insight. Compr Psychiatry 1998, 39:215-219.
23. Hofer A, Kemmler G, Eder U, et al.: Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002, 63:49-53.
24. Angermeyer MC, Matschinger H: [Attitude of family to neuroleptics]. Psychiatr Prax 1999, 26:171-174.
25. Angermeyer MC, Boitz K, Loffler W, et al.: [Attitude of family to clozapine]. Psychiatr Prax 1999, 26:181-187.
26. Walburn J, Gray R, Gournay K, et al.: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001, 179:300-307.
27. Svedberg B, Backenroth-Ohsako G, Lutzen K: On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003, 12:110-118.
28. Patel MX, Nikolaou V, David AS: Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003, 33:83-89.
29. Judge R: Patient perspectives on once-weekly fluoxetine. J Clin Psychiatry 2001, 62(suppl):53-57.
30. Siegel SJ, Winey KI, Gur RE, et al.: Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 2002, 26:817-823.
31. Pekkala E, Merinder L: Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002, CD002831.
32. Hayashi N, Yamashina M, Igarashi Y, Kazamatsuri H: Improvement of patient attitude toward treatment among inpatients with schizophrenia and its related factors: controlled study of a psychological approach. Compr Psychiatry 2001, 42:240-246.
33. Hofer E, Wancata J, Amering M: ["I am a Misunderstood Being on Earth." Concept of illness of patients suffering from schizophrenic psychosis before and after psychoeducational treatment]. Psychiatr Prax 2001, 28:287-291.
34. Angermeyer MC, Held T, Gortler D: [Pro and contra: psychotherapy and psychopharmacotherapy attitude of the public]. Psychother Psychosom Med Psychol 1993, 43:286-292.
35. Angermeyer MC, Matschinger H: Public attitude towards psychiatric treatment. Acta Psychiatr Scand 1996, 94:326-336.
36. Carpenter WT Jr., Gold JM, Lahti AC, et al.: Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 2000, 57:533-538.
37. Roberts LW, Warner TD, Nguyen KD, et al.: Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology (Berl) 2003, 171:58-67.
38. Roberts LW, Warner TD, Brody JL: Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 2000, 157:67-74.
39. Hummer M, Holzmeister R, Kemmler G, et al.: Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry 2003, 64:277-281.